These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 15334273)
21. Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir/ritonavir antiretroviral in HIV-infected patients. Sáez de la Fuente J; Granja V; Escobar I; Collada de la Fuente E; Moreno V; Rubio R J Acquir Immune Defic Syndr; 2009 Mar; 50(3):294-8. PubMed ID: 19194313 [TBL] [Abstract][Full Text] [Related]
22. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. Doco-Lecompte T; Garrec A; Thomas L; Trechot P; May T; Rabaud C AIDS; 2004 Mar; 18(4):705-6. PubMed ID: 15090783 [No Abstract] [Full Text] [Related]
23. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895 [TBL] [Abstract][Full Text] [Related]
24. [No resistance even after 1 year. New drug combination against HIV]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():108. PubMed ID: 11373766 [No Abstract] [Full Text] [Related]
25. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D; Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869 [TBL] [Abstract][Full Text] [Related]
26. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra). Lafeuillade A; Hittinger G; Philip G; Lambry V; Jolly P; Poggi C HIV Clin Trials; 2004; 5(6):392-8. PubMed ID: 15682352 [TBL] [Abstract][Full Text] [Related]
27. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. Gutmann C; Cusini A; Günthard HF; Fux C; Hirschel B; Decosterd LA; Cavassini M; Yerly S; Vernazza PL; AIDS; 2010 Sep; 24(15):2347-54. PubMed ID: 20802298 [TBL] [Abstract][Full Text] [Related]
28. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262 [TBL] [Abstract][Full Text] [Related]
30. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection. Colebunders R; De Schacht C; Vanwolleghem T; Callens S Int J Infect Dis; 2004 Sep; 8(5):315-6. PubMed ID: 15325601 [No Abstract] [Full Text] [Related]